

091865, 193

DOCKET NO: ISIS0064-100 (RTS-0175)

PATENT

In the Claims:

Please amend claim 1 and add new claims 21-30 as follows.

1. (previously presented) An oligomeric compound comprising up to 50 8 to 50 nucleobases in length and comprising SEQ ID NO:38 ~~targeted to a nucleic acid molecule encoding human dual-specific phosphatase 5 (SEQ ID NO:10), wherein said compound inhibits the expression of human dual-specific phosphatase 5 by at least 40%.~~

2. (Original) The compound of claim 1 which is an antisense oligonucleotide.

3. (Canceled).

3. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

4. (Original) The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

5. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

6. (Original) The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

7. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

8. (Original) The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.

DOCKET NO: ISIS0064-100 (RTS-0175)

PATENT

- ⁹10. (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. (Canceled).
- ¹⁰12. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- ¹¹13. (Original) The composition of claim ¹⁰12 further comprising a colloidal dispersion system.
- ¹²14. (Original) The composition of claim ¹⁰12 wherein the compound is an antisense oligonucleotide.
- ¹³15. (Previously presented) A method of inhibiting the expression of dual specific phosphatase 5 in cells or tissues comprising contacting said cells or tissues *in vitro* with the compound of claim 1 so that expression of dual specific phosphatase 5 is inhibited.
- 16-20. (Canceled).
- ¹⁴21. (new) A compound consisting of SEQ ID NO:38.
- ¹⁵22. (new) The compound of claim ¹⁴21 which is an antisense oligonucleotide.
- ¹⁶23. (new) The compound of claim ¹⁵22 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- ¹⁷24. (new) The compound of claim ¹⁶23 wherein the modified internucleoside linkage is a phosphorothioate linkage.

DOCKET NO: ISIS0064-100 (RTS-0175)

PATENT

- 13 ~~25~~. (new) The compound of claim ¹⁵~~22~~ wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 19 ~~26~~. (new) The compound of claim ¹³~~25~~ wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 20 ~~27~~. (new) The compound of claim ¹⁵~~22~~ wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 21 ~~28~~. (new) The compound of claim ²⁰~~27~~ wherein the modified nucleobase is a 5-methylcytosine.
- 22 ~~29~~. (new) The compound of claim ¹⁵~~22~~ wherein the antisense oligonucleotide is a chimeric oligonucleotide.
- 23 ~~30~~. (new) The compound of claim 1 wherein the compound comprises up to 30 nucleobases.